Qiagen N.v. · NYSE:QGEN
Qiagen — Q1 2026 Earnings Presentation
12 slides from Qiagen's earnings presentation, Apr 28, 2026
Slide 1: Preliminary Q1 2026 results
Preliminary Q1 2026 results Committed to solid profitable growth April 27, 2026
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Q1 2026: Overview
Q1 2026: Overview 1 Preliminary Q1 2026: Mixed net sales trends, adj. EPS achieving outlook ● $492 mn net sales (+2% actual, -1% CER vs. ≥1% CER outlook) Net sales Adjusted EPS In $ millions In $ per share ● $0.54 CER adjusted diluted EPS in line with outlook +2% / 2 Strong growth among key pillars,
Slide 4: Q1 2026: Sales performance and key developments
Q1 2026: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) -1% • +9% CER growth, +3% CER growth excl. Parse Sample CER(1) technologies • Parse integration progressing well, on track to exceed 483 492 ~$40 mn FY 2026 sales target • -5% CER
Slide 5: Q1 2026: Portfolio developments
Q1 2026: Portfolio developments Sample technologies – Parse: Oncology portfolio: QIAstat-Dx: Advancing scalable single-cell sequencing Addressing key oncology research needs Advancing syndromic testing solutions Launch of Evercode® Whole Transcriptome Expansion of genomic profiling solutions Launch
Slide 6: FY 2026 sales outlook: Updated perspectives
FY 2026 sales outlook: Updated perspectives ≥+5% CER ~ -1.5 ppts ~ -2 ppts ~+1-2% CER • Reduced immigration • Cautious U.S. Life testing demand Sciences capital (U.S. / Middle East) spending • OEM customer ordering trends • Middle East conflict 2026 outlook QuantiFERON Life Sciences / Updated 2026 o
Slide 7: FY 2026: Leveraging a solid portfolio to drive growth
FY 2026: Leveraging a solid portfolio to drive growth Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Growth pillars total sales (CER) 2026 CER targets ~$720 mn ~$535 mn ~$100 mn ~$160 mn ~$125 mn ~$1.64 bn (February 2026) Updated Updated 2026 CER ~$1.61 bn ~$720 mn ~$500 mn ~$100 mn ~$160 mn ~$125
Slide 8: 2026 sales outlook: H1 vs. H2 updated perspectives
2026 sales outlook: H1 vs. H2 updated perspectives Updated ~+0.5 ppts ~+4% CER ~+1 ppt ~+2 ppts ~+2 ppts ~ -1-2% CER H1 2026 growth End of NeuMoDx, New Sample tech QuantiFERON Better U.S. Life H2 2026 growth outlook Dialunox headwind systems, new returning to Science environment outlook product laun
Slide 9: Q2 and FY 2026: Updated outlook and assumptions
Q2 and FY 2026: Updated outlook and assumptions (As of April 27, 2026) Q2 2026 outlook FY 2026 outlook Net sales ~ -2% CER ~+1-2% CER Anticipated currency impact(1) Positive impact of ~+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.60 CER ≥$2.43 CER Anticipated currency impact(1) Neut
Slide 10: Appendix
QIAGEN Appendix
Slide 11: Q1 2026: Maintaining solid profitability while investing in future growth
Q1 2026: Maintaining solid profitability while investing in future growth Adjusted operating income margin 29.8% ~-1.5 ppts ~-0.7 ppts ~-1.2 ppts ~+1 ppt ~27.4% Q1 2025 Tariffs FX Acquisitions Efficiency program Q1 2026 ppts– Percentage points April 27, 2026 Preliminary Q1 2026 results 11
Slide 12: Your contacts
Your contacts Calendar Daniel Wendorff Vice President Q1 2026 full results May 6, 2026 E-mail: Head of Investor Relations ir@qiagen.com QuantiFERON Spotlight Session May 7, 2026 Internet: Phone: +49 2103 29 11322 E-mail: daniel.wendorff@qiagen.com corporate.QIAGEN.com Annual General Meeting June 202